Furthermore, GPR35 expression was negatively correlated with eight established immunotherapy response signatures and associated with aggressive mutational landscapes.<h4>Discussion</h4>Collectively, our findings identify GPR35 as a novel cancer cell-intrinsic driver of immune evasion and immunotherapy resistance, positioning it as a promising therapeutic target to sensitize "cold" CRC tumors to immune checkpoint blockade. Here, GPR35 is linked to cancer.